CEVA Logistics AG
- ISIN: CH0413237394
- Land: Schweiz
Nachricht vom 11.07.2018 | 07:00
CEVA Logistics AG: CMA CGM receives regulatory approvals for its investment in CEVA
CEVA Logistics AG / Key word(s): Miscellaneous CMA CGM receives regulatory approvals for its investment in CEVA CMA CGM, the third largest container shipping group in the world, made a strategic investment in convertible securities issued by CEVA in a concurrent private placement at the time of CEVA's initial public offering on the SIX Swiss Exchange (the "IPO"). CMA CGM has now obtained all required regulatory approvals and the securities will be converted into registered ordinary shares in the coming days. Following conversion, CMA CGM will hold 24.99% of CEVA's share capital. CMA CGM has entered into a lock-up agreement for one year following the IPO and has agreed not to increase its shareholding in CEVA for six months post-IPO. CEVA and CMA CGM will work together to expand their commercial cooperation and to develop complementary services, which address the increasing customer need for integrated end-to-end solutions. Both companies explore arms-length cooperation and believe that the partnership could create significant value to customers and would be mutually beneficial to both companies. CEVA's CEO, Xavier Urbain, commented: "It is good news that regulatory approvals have been obtained so quickly and we can now fully engage. We are excited about the partnership with CMA CGM."
For additional information please contact: Investors: Cathy Howe
CEVA - Making business flow End of ad hoc announcement |
Interaktiv
Weblinks
GBC-Fokusbox

UniDevice AG: Rekord-Ergebnis in 2018
Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.
Der AKTIONÄR News

20. Februar 18:12 Baidu: Ein Riesenproblem für Anleger
20. Februar 18:00 Wirecard: Exklusiv-Interview – Ehssan Khazaeli will Dan McCrum zur ...
20. Februar 17:57 Das unfassbare Silber-Kursziel
20. Februar 17:52 Wettrennen in der Cloud – Microsoft und Google holen auf
20. Februar 17:05 Tesla-Rivale: Aktie heute +40% - Musk kontert mit ...
News im Fokus

Fresenius Medical Care gibt Ausscheiden von Finanzvorstand Michael Brosnan bekannt
20. Februar 2019, 10:29
Aktuelle Research-Studie
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
20. Februar 2019